Michael Garbee, MD
Neurology · Meridian, MSNPI 1093923146
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,403 and has fallen 81.9% since, to $254 in 2025.
Across 214 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$426
- Lilly USA, LLC$353
- Novartis$347
- Amgen$330
- Teva Pharmaceuticals USA, Inc.$259
- Pfizer$239
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,84599%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $426 |
| Lilly USA, LLC | 19 | $353 |
| Novartis | 23 | $347 |
| Amgen | 17 | $330 |
| Teva Pharmaceuticals USA, Inc. | 11 | $259 |
| Pfizer | 16 | $239 |
| Sanofi | 9 | $184 |
| Lundbeck LLC | 9 | $181 |
| AstraZeneca | 8 | $179 |
| Neurocrine Biosciences, Inc. | 6 | $130 |
| Argenx US, Inc. | 5 | $122 |
| SK Life Science, Inc. | 5 | $108 |
| Johnson & Johnson | 5 | $90 |
| Acadia Pharmaceuticals Inc | 4 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $80 |
| Sunovion Pharmaceuticals Inc. | 5 | $76 |
| UCB, Inc. | 3 | $74 |
| Tanabe Pharma America, Inc. | 4 | $66 |
| ANI Pharmaceuticals, Inc. | 4 | $64 |
| Biogen | 3 | $64 |
| Eisai Inc. | 3 | $62 |
| Biohaven Pharmaceuticals, Inc. | 3 | $45 |
| Mallinckrodt Enterprises LLC | 2 | $44 |
| Amneal Pharmaceuticals LLC | 3 | $43 |
| Avanir Pharmaceuticals, Inc. | 3 | $43 |
| Life Molecular Imaging Ltd | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Catalyst Pharmaceuticals, Inc. | 1 | $23 |
| CSL Behring | 1 | $20 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
| GE HealthCare | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
| Bioventus LLC | 1 | $11 |
How this compares
$3,865 in reported general payments places this provider in the 55th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 13 | $101,009 |
| Austedo XrDeutetrabenazine | 11 | $76,237 |
| Dimethyl Fumarate | 17 | $53,883 |
| QuliptaAtogepant | 24 | $40,825 |
| Emgality PenGalcanezumab-Gnlm | 25 | $33,882 |
| Aimovig AutoinjectorErenumab-Aooe | 26 | $26,351 |
| Pregabalin | 137 | $9,299 |
| Gabapentin | 331 | $8,093 |
| Primidone | 113 | $7,426 |
| Donepezil Hcl | 291 | $3,961 |
| Clobazam | 12 | $3,184 |
| Amitriptyline Hcl | 156 | $2,666 |
| Lacosamide | 22 | $2,646 |
| Memantine Hcl | 92 | $2,567 |
| RivastigmineRivastigmine Tartrate | 46 | $2,552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $64 | $101,00913 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $259 | $76,23711 claims |
| AbbVieQulipta | $426 | $40,82524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 111 neurology providers in Mississippi.
Other neurology in Meridian
- Aamir HashmatMeridian$10K
- Rafique AhmadMeridian$2K
- Stephen LandyTupelo$1.9M
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Ronald SchwartzHattiesburg$352K
- Rajesh SharmaJackson$152K
- Paula WarrenHattiesburg$114K
- Justin GraffTupelo$85K
- Patrick WeldonJackson$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.